Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vebreltinib - Apollomics/Beijing Pearl Biotechnology

Next Previous
Drug Profile

Vebreltinib - Apollomics/Beijing Pearl Biotechnology

Alternative Names: APL-101; Bozitinib - Apollomics/Beijing Pearl Biotechnology; Bozitinib - Beijing Pearl Biotechnology/CBT Pharmaceuticals; CBI-3103; CBT-101; PLB-1001

Latest Information Update: 09 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crown Bioscience
  • Developer Apollomics; Beijing Pearl Biotechnology
  • Class Antineoplastics; Cyclopropanes; Fluorinated hydrocarbons; Indazoles; Pyrazoles; Pyridazines; Small molecules; Triazoles
  • Mechanism of Action Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Registered Glioblastoma; Non-small cell lung cancer
  • Phase II Solid tumours
  • Phase I/II Liver cancer; Renal cell carcinoma

Most Recent Events

  • 31 May 2025 Preregistration for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO)
  • 31 May 2025 Vebreltinib receives priority review status for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO)
  • 31 May 2025 Efficacy and adverse events data from a phase-I/II KYLIN-1 trial in Non-small cell lung cancer released by Avistone Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top